Press Releases

Jan. 7, 2008
Coronado Initiates Phase I Clinical Trial of Rationally Designed Fourth Generation Doxorubicin Analogue

Jan. 28, 2008
Study Shows Coronado Biosciences’ Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models

Company News

August 9, 2008
Cancer victim treated with daughter's cells in world first

July 14, 2008
Emerging Company Profile; Coronado: Cancer conquistador by Aaron Bouchie; Senior Writer. BioCentury vol 16 (32) page A16;